Erschienen in:
01.08.2006 | Review
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy
A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
verfasst von:
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, B. Zinman
Erschienen in:
Diabetologia
|
Ausgabe 8/2006
Einloggen, um Zugang zu erhalten
Excerpt
The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century, and the recognition that achieving specific glycaemic goals can substantially reduce morbidity, have made the effective treatment of hyperglycaemia a top priority [
1‐
3]. While the management of hyperglycaemia, the hallmark metabolic abnormality associated with type 2 diabetes, has historically had centre stage in the treatment of diabetes, therapies directed at other coincident features, such as dyslipidaemia, hypertension, hypercoagulability, obesity and insulin resistance, have also been a major focus of research and therapy. Maintaining glycaemic levels as close to the non-diabetic range as possible has been demonstrated to have a powerful beneficial impact on diabetes-specific complications, including retinopathy, nephropathy and neuropathy in the setting of type 1 diabetes [
4,
5]; in type 2 diabetes, more intensive treatment strategies have likewise been demonstrated to reduce complications [
6‐
8]. Intensive glycaemic management resulting in lower HbA
1c levels has also been shown to have a beneficial effect on cardiovascular disease (CVD) complications in type 1 diabetes [
9,
10]; however, the role of intensive diabetes therapy on CVD in type 2 diabetes remains under active investigation [
11,
12]. Some therapies directed at lowering glucose levels have additional benefits with regard to CVD risk factors, while others lower glucose without additional benefits. …
